For bladder cancer detection
Cancer is one of the leading causes of death in the industrial world. Despite our advancing knowledge of cancer, there is still a need for additional information for management of the disease. Improvement to patient care can be expected if clinicians have more information on prognosis, early indications of treatment response, and disease progression. To improve cancer patient management, there is a clear need for efficient diagnostics tools to capture this critical clinical data. IDL Biotech offers a panel of in vitro diagnostic tumor activity markers for use in the most common types of cancer, including breast, colorectal, lung, ovarian and prostate cancer. IDL tumor markers offer enhanced sensitivity and lead times. Our tests provide clinicians with greater insight into disease status to improve cancer patient management. IDL assays are available in different formats, including enzymatic (ELISA) assay, radiometric (IRMA) assay, and point-of-care (POC) test.
• Help clinicians establish prognostic information • Used during treatment monitoring for efficient therapy outcomes
• Used during regular patient follow-up for early detection of progression and recurrence